A practical reference on Thymosin beta-4: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.
Regulatory status differs by country, but TB-500 is not an approved pharmaceutical in major jurisdictions. It is commonly sold as a research chemical for laboratory use, which places responsibility for identity and purity on the supplier and the laboratory. Published human data are limited, and most reports involve preclinical models or cell culture. Questions about whether the fragment mimics all actions of thymosin beta-4, and under which conditions, remain open. Independent verification of any material is therefore a practical requirement in research settings.
TB-500 is a synthetic heptapeptide with the sequence Ac-LKKTETQ. It corresponds to a short N-terminal region of thymosin beta-4, a 43-amino-acid protein found in many cell types. The fragment contains an actin-binding motif, which is one reason it appears in laboratory studies of cell migration and cytoskeletal dynamics. TB-500 is not the full-length protein and is produced as a research chemical rather than an approved therapeutic agent. Its molecular weight is approximately 889 Da.
Several names appear in scientific and commercial contexts for this peptide. The label TB-500 is informal and does not follow standard biochemical nomenclature. Research articles more often describe the compound as a thymosin beta-4 fragment, Tβ4 fragment, or by its sequence Ac-LKKTETQ. Confusing TB-500 with full-length thymosin beta-4 can lead to incorrect assumptions about activity because the fragment lacks the remaining residues of the parent protein. The relationship between fragment and parent protein remains an active area of study.
Proposed activity centers on actin sequestration and on the movement of cells during repair processes. In cell culture and animal models, the fragment has been associated with migration, tube formation, and tissue remodeling. These observations are frequently described as preliminary, because most published work uses rodent or in vitro systems rather than controlled human trials. Whether the short fragment reproduces the effects of the full protein remains an open question, and the relationship between dose, route, and measured outcome is not well characterized.
The compound circulates in the literature as a research reagent rather than an approved therapeutic. Regulatory agencies in several countries have not authorized it for medical use, and sporting bodies list related thymosin beta-4 peptides among prohibited substances. Suppliers typically market it with a purity figure and a certificate of analysis, while peer-reviewed clinical reports remain sparse. Discussions therefore often separate laboratory findings from anecdotal reports, and reviewers tend to note the small size and methodological limits of the available studies.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C38H68N10O14 | Calculated for the acetylated heptapeptide |
| Molecular weight | ~889 Da | Monoisotopic mass approximately 889.0 Da |
| Amino acid sequence | Ac-LKKTETQ | N-terminal acetylated seven-residue peptide |
| Appearance | White to off-white powder | Typically supplied as a lyophilized solid |
| Solubility class | Water-soluble | Peptides of this size generally dissolve in aqueous media |
TB-500 is a synthetic seven-residue peptide whose sequence, LKKTETQ, matches the N-terminal actin-binding region of thymosin beta-4. It is usually supplied in an N-terminally acetylated form, a modification that blocks the free amino terminus and can influence behavior in solution. In the research literature the same sequence appears under several names, including thymosin beta-4 fragment and shortened thymosin beta-4. Because it is a short peptide rather than the full 43-residue parent protein, its measured properties differ from those reported for thymosin beta-4 as a whole, and the two are not interchangeable in experimental design.
Thymosin beta-4 itself is a small, widely expressed protein that sequesters monomeric actin and participates in cell migration, angiogenesis, and tissue repair. Researchers have examined the shortened fragment as a possible mimic of some of these activities, reasoning that the actin-binding motif lies within the first few residues. Binding to monomeric actin has been observed in cell-free systems. Whether the fragment reproduces the broader effects of the full protein in living tissue remains an open question, and findings from animal models are frequently cited without a clear bridge to human physiology.
Full-length thymosin beta-4 consists of roughly forty-three amino acids and ranks among the more abundant small proteins in the cytoplasm. The fragment is much shorter, so it cannot reproduce every function attributed to the intact molecule. In cell culture, short actin-binding motifs can interfere with filament dynamics and cell movement, but such observations come from controlled experiments rather than from whole-animal work. Whether a truncated fragment produces the same effects as the parent protein remains an open question.
Interest in the peptide grew during the 2000s and 2010s, when studies of tendon and ligament injuries in horses reported changes in lesion size after treatment. Those reports circulated widely outside the scientific literature and shaped much of the current online discussion. Subsequent reviews noted inconsistent study design, small groups, and a shortage of independent replication. Popular descriptions often blur the line between the fragment, the complete protein, and unrelated growth factors, which complicates comparisons across sources.
TB-500 is a synthetic peptide whose sequence corresponds to a short fragment near the N-terminus of thymosin beta-4, a small protein present in most mammalian cells. The fragment is commonly cited as containing the actin-binding region of the parent molecule, which is why it appears in laboratory work on cell migration and tissue repair. Suppliers distribute it as a lyophilised powder intended for research use. Its identity is defined by amino acid sequence and by the presence of an acetyl group on the N-terminal residue.
== Diagnosis == The diagnosis of muscular dystrophy is based on the results of muscle biopsy, increased creatine phosphokinase (CpK3), electromyography, and genetic testing. A physical examination and the patient's medical history will help the doctor determine the type of muscular dystrophy. Specific muscle groups are affected by different types of muscular dystrophy. An MRI can be used to assess the white matter of the nervous system and measure the merosin levels in young boys. An absence of merosin in young boys will result with neurological deficits and changes in the white matter.
Engrafting an immunodeficient mouse with functional human cells can be achieved by intravenous injections of human cells and tissue into the mouse, and/or creating a genetically modified mouse from human genes. These models have been instrumental in studying human diseases, immune responses, and therapeutic interventions. This section highlights the various humanized mice models developed using the different methods.
== Immunomodulatory properties == Beyond its antibacterial activity, fosfomycin has been shown to modulate immune responses. Recent studies demonstrate that it can reduce the production of pro-inflammatory cytokines (e.g., TNF-α, IL-1β, IL-6), inhibit key inflammatory pathways such as NF-κB and MAPK, and increase anti-inflammatory mediators like IL-10. Additionally, fosfomycin may suppress T-cell proliferation, reduce neutrophil activation, and enhance tissue repair processes. These findings suggest potential applications in conditions involving dysregulated inflammation, such as sepsis or chronic wounds.
== 23S rRNA Helix 26a == The 23S ribosomal RNA is composed of six domains forming a complex network of molecular interactions. A central single-stranded region connects all of the domains through base-pairing of the two halves, forming Helix 26a. Some consider Helix 26a to be Domain 0 due to its action as a central core and compact folding unit. Comparison of 23S and 28S ribosomal RNA sequences across species demonstrate conservation of Helix 26a. Helices continue to provide the support as the backbone of domain architecture.
Sources: en.wikipedia.org
HOCH(CH2OH)2 + HCl → HOCH(CH2Cl)(CH2OH) + H2O The same compound can be produced by hydrolysis of epichlorohydrin. Epoxidation by reaction with epichlorohydrin and a Lewis acid yields Glycerol triglycidyl ether.
=== RNP-MaP site identification === RNP-MaP sites are defined as protein bound nucleotides. SDA and UV treated and UV only treated sample sequence reads are aligned and mutations are counted using ShapeMapper2 software. The SDA or RNP-MaP reactivity for a nucleotide is the ratio of the crosslinked (SDA and UV treated) mutational frequency to the un-crosslinked (UV only) mutation frequency. Using differential mutational signatures, RNP-MaP sites are identified based on universal normalization factors and thresholds on each RNA nucleotide (U, A, C, and G) derived from analysis of ribonucleoproteins of known structure. A nucleotide is identified as a RNP-MaP site if it passes three filters:
== Early life and education == Osborn was born in Darlington, UK on 16 December 1940. Osborn completed high school education at Cheltenham Ladies' College and university education at Newnham College, Cambridge University where she was graduated in Mathematics and Physics in 1962. She received a masters in biophysics at Pennsylvania State University in 1963. Her PhD on mutagenesis in nonsense mutations in bacteria was awarded by Pennsylvania State University in 1972.
Sources: en.wikipedia.org
The valence of an element can be defined either as the number of hydrogen atoms that can combine with it to form a simple binary hydride, or as twice the number of oxygen atoms that can combine with it to form a simple binary oxide (that is, not a peroxide or a superoxide). The valences of the main-group elements are directly related to the group number: the hydrides in the main groups 1–2 and 13–17 follow the formulae MH, MH2, MH3, MH4, MH3, MH2, and finally MH. The highest oxides instead increase in valence, following the formulae M2O, MO, M2O3, MO2, M2O5, MO3, M2O7. Today the notion of valence has been extended by that of the oxidation state, which is the formal charge left on an element when all other elements in a compound have been removed as their ions. The electron configuration suggests a ready explanation from the number of electrons available for bonding; indeed, the number of valence electrons starts at 1 in group 1, and then increases towards the right side of the periodic table, only resetting at 3 whenever each new block starts. Thus in period 6, Cs–Ba have 1–2 valence electrons; La–Yb have 3–16; Lu–Hg have 3–12; and Tl–Rn have 3–8. However, towards the right side of the d- and f-blocks, the theoretical maximum corresponding to using all valence electrons is not achievable at all; the same situation affects oxygen, fluorine, and the light noble gases up to krypton.
Experiment D-8 used five dosimeters to measure the radiation in the spacecraft environment. Of particular interest was the South Atlantic Anomaly. Experiment D-9 was an experiment in simple spacecraft navigation where the crew used a sextant to measure their position using the stars. The objective was to investigate the feasibility of using this technique for lunar flights on the Apollo program. Experiments S-5 and S-6 were both photography experiments where they used a 70-millimeter Hasselblad camera to photograph the weather and terrain below them. There were two medical experiments: M-3 and M-4. The first was a bungee cord that the crew used for exercise. They said, after the mission, that this got harder as the mission went on, though this may have been due to a lack of sleep. The second was the phonocardiogram experiment, which had sensors attached to their bodies that measured heartbeat rates, especially during liftoff, EVA, and reentry. There were four engineering experiments:
Temporary muscle weakness Brain fog Fatigue Anxiety Temporary thought disorder, or inability to concentrate Visual problems, such as blurred vision or double vision Headaches Shaking/Trembling Thirst If a person experiences any of these symptoms, a visit to a qualified medical practitioner is advised, and diagnostic blood testing, such as Fasting Insulin Levels, may be required.
Acting on the nuclear mineralocorticoid receptors (MR) within the principal cells of the distal tubule and the collecting duct of the kidney nephron, it upregulates and activates the basolateral Na+/K+ pumps, which pumps three sodium ions out of the cell, into the interstitial fluid and two potassium ions into the cell from the interstitial fluid. This creates a concentration gradient which results in reabsorption of sodium (Na+) ions and water (which follows sodium) into the blood, and secreting potassium (K+) ions into the urine (lumen of collecting duct). Aldosterone upregulates epithelial sodium channels (ENaCs) in the collecting duct and the colon, increasing apical membrane permeability for Na+ and thus absorption. Cl− is reabsorbed in conjunction with sodium cations to maintain the system's electrochemical balance. Aldosterone stimulates the secretion of K+ into the tubular lumen. Aldosterone stimulates Na+ and water reabsorption from the gut, salivary and sweat glands in exchange for K+. Aldosterone stimulates secretion of H+ via the H+/ATPase in the intercalated cells of the cortical collecting tubules Aldosterone upregulates expression of NCC in the distal convoluted tubule chronically and its activity acutely. Aldosterone is responsible for the reabsorption of about 2% of filtered sodium in the kidneys, which is nearly equal to the entire sodium content in human blood under normal glomerular filtration rates. Aldosterone, probably acting through mineralocorticoid receptors, may positively influence neurogenesis in the dentate gyrus.
Sources: en.wikipedia.org
TB-500 is a synthetic heptapeptide corresponding to a fragment of thymosin beta-4. It is used in laboratory research and is not an approved drug.
No. Thymosin beta-4 is a 43-amino-acid protein, while TB-500 represents only a short N-terminal segment. The two should not be treated as interchangeable in experimental design.
It is often called a thymosin beta-4 fragment, Tβ4 fragment, or Ac-LKKTETQ. The name TB-500 is mainly a commercial or catalog label rather than a formal chemical name.
TB-500 is a name used for a short synthetic peptide fragment taken from the actin-binding region of thymosin beta-4. Material sold under this label is usually a lyophilized powder supplied for laboratory research rather than a licensed medicine. The commonly cited sequence is LKKTETQ.